Cargando…
Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
We report on an extensive structure–activity relationship study of novel PI4K IIIβ inhibitors. The purine derivative of the potent screening hit T-00127-HEV1 has served as a suitable starting point for a thorough investigation of positions 8 and 2. While position 8 of the purine scaffold can only be...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127540/ https://www.ncbi.nlm.nih.gov/pubmed/27090557 http://dx.doi.org/10.1016/j.bmcl.2016.04.002 |
_version_ | 1783516382696046592 |
---|---|
author | Šála, Michal Kögler, Martin Plačková, Pavla Mejdrová, Ivana Hřebabecký, Hubert Procházková, Eliška Strunin, Dmytro Lee, Gary Birkus, Gabriel Weber, Jan Mertlíková-Kaiserová, Helena Nencka, Radim |
author_facet | Šála, Michal Kögler, Martin Plačková, Pavla Mejdrová, Ivana Hřebabecký, Hubert Procházková, Eliška Strunin, Dmytro Lee, Gary Birkus, Gabriel Weber, Jan Mertlíková-Kaiserová, Helena Nencka, Radim |
author_sort | Šála, Michal |
collection | PubMed |
description | We report on an extensive structure–activity relationship study of novel PI4K IIIβ inhibitors. The purine derivative of the potent screening hit T-00127-HEV1 has served as a suitable starting point for a thorough investigation of positions 8 and 2. While position 8 of the purine scaffold can only bear a small substituent to maintain the inhibitory activity, position 2 is opened for extensive modification and can accommodate even substituted phenyl rings without the loss of PI4K IIIβ inhibitory activity. These empirical observations nicely correlate with the results of our docking study, which suggests that position 2 directs towards solution and can provide the necessary space for the interaction with remote residues of the enzyme, whereas the cavity around position 8 is strictly limited. The obtained compounds have also been subjected to antiviral screening against a panel of (+)ssRNA viruses. |
format | Online Article Text |
id | pubmed-7127540 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71275402020-04-08 Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors Šála, Michal Kögler, Martin Plačková, Pavla Mejdrová, Ivana Hřebabecký, Hubert Procházková, Eliška Strunin, Dmytro Lee, Gary Birkus, Gabriel Weber, Jan Mertlíková-Kaiserová, Helena Nencka, Radim Bioorg Med Chem Lett Article We report on an extensive structure–activity relationship study of novel PI4K IIIβ inhibitors. The purine derivative of the potent screening hit T-00127-HEV1 has served as a suitable starting point for a thorough investigation of positions 8 and 2. While position 8 of the purine scaffold can only bear a small substituent to maintain the inhibitory activity, position 2 is opened for extensive modification and can accommodate even substituted phenyl rings without the loss of PI4K IIIβ inhibitory activity. These empirical observations nicely correlate with the results of our docking study, which suggests that position 2 directs towards solution and can provide the necessary space for the interaction with remote residues of the enzyme, whereas the cavity around position 8 is strictly limited. The obtained compounds have also been subjected to antiviral screening against a panel of (+)ssRNA viruses. Elsevier Ltd. 2016-06-01 2016-04-05 /pmc/articles/PMC7127540/ /pubmed/27090557 http://dx.doi.org/10.1016/j.bmcl.2016.04.002 Text en © 2016 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Šála, Michal Kögler, Martin Plačková, Pavla Mejdrová, Ivana Hřebabecký, Hubert Procházková, Eliška Strunin, Dmytro Lee, Gary Birkus, Gabriel Weber, Jan Mertlíková-Kaiserová, Helena Nencka, Radim Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors |
title | Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors |
title_full | Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors |
title_fullStr | Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors |
title_full_unstemmed | Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors |
title_short | Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors |
title_sort | purine analogs as phosphatidylinositol 4-kinase iiiβ inhibitors |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127540/ https://www.ncbi.nlm.nih.gov/pubmed/27090557 http://dx.doi.org/10.1016/j.bmcl.2016.04.002 |
work_keys_str_mv | AT salamichal purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT koglermartin purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT plackovapavla purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT mejdrovaivana purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT hrebabeckyhubert purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT prochazkovaeliska purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT strunindmytro purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT leegary purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT birkusgabriel purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT weberjan purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT mertlikovakaiserovahelena purineanalogsasphosphatidylinositol4kinaseiiibinhibitors AT nenckaradim purineanalogsasphosphatidylinositol4kinaseiiibinhibitors |